Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Elkins

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Neurology and Therapy|November 26, 2024
Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular DystrophyCraig M McDonald, Jacob S Elkins, Sai Dharmarajan, et al.
JAMA Neurology|May 12, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical TrialKrista Vandenborne, Glenn A Walter, Volker Straub, et al.
Nature Medicine|October 9, 2024
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trialJerry R Mendell, Francesco Muntoni, Craig M McDonald, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Neurology and Therapy|November 26, 2024
Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular DystrophyCraig M McDonald, Jacob S Elkins, Sai Dharmarajan, et al.
JAMA Neurology|May 12, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical TrialKrista Vandenborne, Glenn A Walter, Volker Straub, et al.
Nature Medicine|October 9, 2024
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trialJerry R Mendell, Francesco Muntoni, Craig M McDonald, et al.
Pageof 5